91,503 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Purchased by Raymond James Financial Inc.

Raymond James Financial Inc. acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 91,503 shares of the biopharmaceutical company's stock, valued at approximately $65,180,000. Raymond James Financial Inc. owned 0.08% of Regeneron Pharmaceuticals at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of REGN. Howe & Rusling Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 3.4% in the 3rd quarter. Howe & Rusling Inc. now owns 462 shares of the biopharmaceutical company's stock worth $486,000 after acquiring an additional 15 shares during the last quarter. Willner & Heller LLC lifted its stake in Regeneron Pharmaceuticals by 3.9% during the fourth quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company's stock worth $284,000 after purchasing an additional 15 shares in the last quarter. OLD Second National Bank of Aurora boosted its position in shares of Regeneron Pharmaceuticals by 0.5% during the fourth quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company's stock worth $2,025,000 after buying an additional 15 shares during the period. Sigma Planning Corp grew its stake in shares of Regeneron Pharmaceuticals by 4.1% in the third quarter. Sigma Planning Corp now owns 409 shares of the biopharmaceutical company's stock valued at $430,000 after buying an additional 16 shares in the last quarter. Finally, GLOBALT Investments LLC GA raised its holdings in shares of Regeneron Pharmaceuticals by 1.5% in the 3rd quarter. GLOBALT Investments LLC GA now owns 1,067 shares of the biopharmaceutical company's stock valued at $1,122,000 after buying an additional 16 shares during the period. Institutional investors and hedge funds own 83.31% of the company's stock.

Remove Ads

Regeneron Pharmaceuticals Stock Performance

REGN stock traded down $26.20 on Wednesday, hitting $691.96. The company's stock had a trading volume of 441,023 shares, compared to its average volume of 925,534. The stock has a market cap of $75.65 billion, a price-to-earnings ratio of 18.08, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The firm has a 50 day moving average of $697.08 and a two-hundred day moving average of $842.19. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to analysts' expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business's revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the company earned $11.86 earnings per share. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.51%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals's payout ratio is currently 2.30%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on REGN shares. Piper Sandler lowered their target price on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating for the company in a report on Monday, January 27th. Canaccord Genuity Group lowered shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, December 17th. Leerink Partners raised shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and upped their target price for the stock from $762.00 to $834.00 in a research note on Wednesday, February 5th. TD Cowen reduced their target price on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating on the stock in a report on Tuesday, February 4th. Finally, Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 5th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.